文献速递肾小球疾病遗传性与小管间质肾病

新突变扩展FAT1肾病谱并揭示Hippo信号改变

Expanding the Spectrum of FAT1 Nephropathies by Novel Mutations That Affect Hippo Signaling.
PubMed 文献 · Kidney Int Rep · 2021-01-29

研究纳入4例FAT1相关肾病患者(3个家系),进行临床遗传学分析并与既往病例对比。患者均表现眼部表型及异质性肾脏表型,尿液上皮细胞显示Hippo通路MST和YAP磷酸化降低、YAP靶基因转录上调。错义突变者表型多样,截短突变者表型较一致。

要点

  • FAT1相关肾病可表现为眼部表型合并异质性肾脏病变。
  • 截短突变者表型较一致,错义突变者表型高度多样。
  • Hippo信号改变和YAP去抑制可能是FAT1肾病新机制。

核心结论

  • 新发现的FAT1突变扩展了FAT1相关肾病谱,截短突变者表型更一致,错义突变者表型高度多样。

研究设计与样本

  • 研究纳入4例FAT1相关疾病患者(来自3个家系),进行临床和遗传学表征,并与既往发表患者比较。

主要发现

  • 4例患者中3例为纯合截短变异,1例为复合杂合错义变异。
  • 所有患者均有眼科表型,肾脏表型从肾功能正常到早发终末期肾衰竭不等。
  • 患者来源尿液肾上皮细胞显示MST和YAP磷酸化降低,YAP靶基因转录上调。

临床怎么用

  • 对疑似FAT1肾病患者应关注眼部表型,并考虑基因检测明确突变类型。

局限性

  • 样本量小(4例患者),需更大队列验证基因型-表型关联。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Disease-causing mutations in the protocadherin FAT1 have been recently described both in patients with a glomerulotubular nephropathy and in patients with a syndromic nephropathy. METHODS: We identified 4 patients with FAT1-associated disease, performed clinical and genetic characterization, and compared our findings to the previously published patients. Patient-derived primary urinary epithelial cells were analyzed by quantitative polymerase chain reaction (qPCR) and immunoblotting to identify possible alterations in Hippo signaling. RESULTS: Here we expand the spectrum of FAT1-associated disease with the identification of novel FAT1 mutations in 4 patients from 3 families (homozygous truncating variants in 3, compound heterozygous missense variants in 1 patient). All patients show an ophthalmologic phenotype together with heterogeneous renal phenotypes ranging from normal renal function to early-onset end-stage kidney failure. Molecular analysis of primary urine-derived urinary renal epithelial cells revealed alterations in the Hippo signaling cascade with a decreased phosphorylation of both the core kinase MST and the downstream effector YAP. Consistently, we found a transcriptional upregulation of bona fide YAP target genes. CONCLUSION: A comprehensive review of the here identified patients and those previously published indicates a highly diverse phenotype in patients with missense mutations but a more uniform and better recognizable phenotype in the patients with truncating mutations. Altered Hippo signaling and de-repressed YAP activity might be novel contributing factors to the pathomechanism in FAT1-associated renal disease.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Fabretti F, Tschernoster N, Erger F, et al. Expanding the Spectrum of FAT1 Nephropathies by Novel Mutations That Affect Hippo Signaling. Kidney Int Rep. 2021. PMID: 34013115. doi:10.1016/j.ekir.2021.01.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。